PROVECTUS BIOPHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 25.00 thousand shares for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2023-03-30

PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2021-12-31 was 0.00 shares.
PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2021 was 25.00K shares, a 60.00% decline from fiscal 2020.
PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2020 was 62.50K shares, a 85.29% decline from fiscal 2019.
PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2019 was 425.00K shares.

Period end	Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month	Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month	Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month
2021-12-31	0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30		25.00K shares 10-K · filed 2023-03-30
2021-09-30		25.00K shares 10-Q · filed 2021-11-10
2020-12-31			62.50K shares 10-K · filed 2022-03-29
2019-12-31			425.00K shares 10-K · filed 2021-03-02